Cochrane · systematic review · CD011690
Short‐acting erythropoiesis‐stimulating agents for anaemia in predialysis patients
Hahn, D, Esezobor, CI, Elserafy, N, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
18
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 11.1%Low 12 · 66.7%Moderate 4 · 22.2%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Epoetin alpha every 2 weeks versus to weekly for anaemia in CKD patients not receiving dialysis
Population: anaemia in predialysis patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in Hb level Epoetin alpha every 2 weeks vs to weekly | no estimate extracted | 4 studies · 798 participants | Low Downgraded: risk of bias |
Number reaching target Hb Epoetin alpha every 2 weeks vs to weekly | RR 0.96 [0.93, 0.99] | 4 studies · 798 participants | Low Downgraded: risk of bias |
Number of deaths Epoetin alpha every 2 weeks vs to weekly | RR 0.89 [0.38, 2.07] | 4 studies · 838 participants | Low Downgraded: risk of bias |
Adverse events: RBC transfusions Epoetin alpha every 2 weeks vs to weekly | RR 1.56 [0.71, 3.45] | 3 studies · 580 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Adverse events: hypertension Epoetin alpha every 2 weeks vs to weekly | RR 0.85 [0.55, 1.32] | 4 studies · 838 participants | Moderate Downgraded: risk of bias |
Adverse events: thrombovascular events Epoetin alpha every 2 weeks vs to weekly | RR 1.41 [0.67, 3] | 4 studies · 838 participants | Low Downgraded: risk of bias |
Epoetin alfa every four weeks versus with every two weeks in CKD patients not receiving dialysis
Population: anaemia in predialysis patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in Hb level Epoetin alfa every four weeks vs with every two weeks | no estimate extracted | 3 studies · 671 participants | Very low Downgraded: risk of bias |
Number reaching target Hb Epoetin alfa every four weeks vs with every two weeks | RR 0.95 [0.84, 1.07] | 3 studies · 687 participants | Very low Downgraded: risk of bias |
Number of deaths Epoetin alfa every four weeks vs with every two weeks | RR 0.95 [0.33, 2.75] | 3 studies · 724 participants | Low Downgraded: risk of bias |
Adverse events: RBC transfusions Epoetin alfa every four weeks vs with every two weeks | RR 1.26 [0.53, 2.98] | 2 studies · 470 participants | Low Downgraded: risk of bias |
Adverse events: hypertension Epoetin alfa every four weeks vs with every two weeks | RR 1.02 [0.62, 1.69] | 3 studies · 724 participants | Moderate Downgraded: risk of bias |
Adverse events: arteriovenous complications Epoetin alfa every four weeks vs with every two weeks | RR 1.02 [0.39, 2.68] | 3 studies · 724 participants | Low Downgraded: risk of bias |
Epoetin theta versus epoetin beta in CKD patients not receiving dialysis
Population: anaemia in predialysis patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Final Hb Epoetin theta vs epoetin beta | no estimate extracted | 1 study · 288 participants | Moderate Downgraded: indirectness |
Mean weekly epoetin dose Epoetin theta vs epoetin beta | no estimate extracted | 1 study · 288 participants | Low Downgraded: indirectness |
Deaths Epoetin theta vs epoetin beta | RR 2.46 [0.29, 20.77] | 1 study · 288 participants | Low Downgraded: imprecision, indirectness |
Adverse events: hypertension Epoetin theta vs epoetin beta | RR 0.35 [0.11, 1.08] | 1 study · 288 participants | Moderate Downgraded: imprecision, indirectness |
Adverse events: RBC transfusions Epoetin theta vs epoetin beta | RR 1.48 [0.06, 36.1] | 1 study · 288 participants | Low Downgraded: imprecision, indirectness |
Adverse events: discontinuation of therapy Epoetin theta vs epoetin beta | RR 1.77 [0.68, 4.63] | 1 study · 288 participants | Low Downgraded: imprecision, indirectness |